Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Depomed Inc    DEPO

Delayed Quote. Delayed  - 02/08 03:59:58 pm
15.22 USD   -5.70%
02/08 Depomed Announces Favorable Markman Ruling in Nucynta® and Nucynt..
02/04 DEPOMED : to Present at Healthcare Conferences in February
02/04 DEPOMED : to Present at Healthcare Conferences in February
Analysis summary4-Traders Strategies 

Depomed Inc : Back to the USD 7 level

02/13/2013 | 09:19am
Opinion : Bullish above USD 6.6
Target price : USD 7 Potential: 4.32%
Stop loss: USD 6.57

From a fundamental viewpoint, the company is strong. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year. In addition the publication of the third quarter of 2012 showed an incredible growth of turnover by more than 100% at USD 33.3 million compared to the same period the previous year. The growing business should allow the security to continue its ascension.

Technically, the security is in an uptrend on all time scales. Prices are coming back to the USD 6.6 short term support, level corresponding to the 20-day moving average. This configuration should allow the stock to bounce towards the USD 7 long term resistance, which will be the first target price.

According to both technical and fundamental elements, it seems opportune to take a long position at the current price. The bullish trend should allow the security to reach the USD 7 resistance. A stop loss will be placed under the USD 6.6 short term support to avoid a downtrend.

Depomed Inc : Depomed Inc : Back to the USD 7 level

© Zonebourse.com 2013

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Financial Ratios

Size 2015e 2016e
Capitalization 921 M$ -
Entreprise Value (EV) 1 453 M$ 1 297 M$
Valuation 2015e 2016e
P/E ratio (Price / EPS) 29,6x
Capitalization / Revenue 2,68x 1,82x
EV / Revenue 4,23x 2,56x
EV / EBITDA 14,4x 6,69x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,87x 3,85x
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) 20,8% 30,5%
operating Leverage (Delta EBIT / Delta Sales) - 2,46x
Net Margin (Net Profit / Revenue) -14,2% 2,81%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) 20,2% 56,8%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   0,66% 0,49%
Cash Flow / Sales - 231%
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 5,26x 1,94x
Income Statement Evolution
More Financials
EPS Revisions